|
Study cohort |
No CMV events |
CMV events |
|
N = 139 |
N = 76 |
N = 63 |
Age (years) |
|
|
|
Mean ± SD |
49.8 ± 12.64 |
|
|
Sex (male) |
83 (60%) |
47 (62%) |
36 (57%) |
Underlying disease |
|
|
|
Idiopathic pulmonary fibrosis |
59 (42.4%) |
33 (43%) |
26 (40%) |
Chronic obstructive pulmonary disease |
35 (25.2%) |
17 (22%) |
18 (28%) |
Cystic fibrosis |
14 (10%) |
11 (14%) |
3 (5%) |
Miscellaneous |
31 (22.4%) |
15 (21%) |
16 (25%) |
Types of transplant |
|
|
|
Single lung |
96 (69%) |
49 (64%) |
46 (73%) |
Double lung |
43 (31%) |
26 (36%) |
17 (27%) |
Duration of prophylaxis (months) Median (min. - max.) |
4 (1.5 - 9) |
|
|
Donor/receptor serological status |
|
|
|
CMV D+/R- |
15 (10.7%) |
6 (8%) |
9 (14%) |
CMV D-/R- |
16 (11.5%) |
13 (17%) |
3 (5%) |
CMV D-/R+ |
25 (18%) |
17 (22%) |
8 (13%) |
CMV D+/R+ |
83 (57%) |
40 (53%) |
43 (68%) |
Rejection requiring increased immunosuppression |
47 (34%) |
26 (34%) |
21(33%) |